{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:41:42Z","timestamp":1792618902464,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.critrevonc.2026.105652","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:07:10Z","timestamp":1792249630000},"page":"105652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prognostic value of circulating tumor DNA in esophageal and gastric cancer by treatment stage: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"228","author":[{"given":"Shaoqing","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyuan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeqi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-2436","authenticated-orcid":false,"given":"Bangsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105652_bib1","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1515\/cclm-2012-0320","article-title":"Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival","volume":"51","author":"Balgkouranidou","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.critrevonc.2026.105652_bib2","first-page":"229","article-title":"Global cancer statistics 2022, GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105652_bib3","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1097\/SLA.0000000000005177","article-title":"Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma","volume":"276","author":"Cabalag","year":"2022","journal-title":"Ann. Surg."},{"key":"10.1016\/j.critrevonc.2026.105652_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doag048","article-title":"Assessment of methylated BCAT1 and IKZF1 circulating tumor DNA as a prognostic biomarker in esophagogastric adenocarcinomas","volume":"39","author":"Chan","year":"2026","journal-title":"Dis. Esophagus"},{"key":"10.1016\/j.critrevonc.2026.105652_bib5","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41467-024-46307-7","article-title":"Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab","volume":"15","author":"Chen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105652_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s43556-025-00310-6","article-title":"Circulating tumor DNA as a marker of molecular residual disease in resected esophageal squamous cell carcinoma","volume":"6","author":"Fang","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.critrevonc.2026.105652_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0335654","article-title":"5-hydroxymethylcytosines from circulating cell-free DNA as noninvasive prognostic markers for gastric cancer","volume":"20","author":"Fu","year":"2025","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105652_bib8","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/carcin\/bgab088","article-title":"Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer","volume":"42","author":"Fujisawa","year":"2021","journal-title":"Carcinog."},{"key":"10.1016\/j.critrevonc.2026.105652_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70446","article-title":"Gene-specific ctDNA dynamics predict tumour burden and survival outcomes in ESCC, A prospective cohort study","volume":"15","author":"Gu","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105652_bib10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s10120-025-01621-x","article-title":"Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer","volume":"28","author":"He","year":"2025","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2026.105652_bib11","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO-25-00948","article-title":"Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy","volume":"43","author":"Hoeppner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184417","article-title":"Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal Cancer","volume":"14","author":"Hofste","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105652_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s44276-025-00158-x","article-title":"Circulating tumor DNA monitoring detects minimal residual disease and predicts outcomes in patients with esophageal adenocarcinoma or squamous cell carcinoma after esophagectomy","volume":"3","author":"Hu","year":"2025","journal-title":"BJC Rep."},{"key":"10.1016\/j.critrevonc.2026.105652_bib14","article-title":"Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers","volume":"6","author":"Huffman","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10120-024-01556-9","article-title":"Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer","volume":"28","author":"Iden","year":"2025","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2026.105652_bib16","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s10120-026-01743-w","article-title":"Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma","volume":"29","author":"Iden","year":"2026","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2026.105652_bib17","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1038\/s41598-023-32645-x","article-title":"The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy","volume":"13","author":"Inagaki","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105652_bib18","doi-asserted-by":"crossref","first-page":"14027","DOI":"10.1038\/s41598-024-63486-x","article-title":"Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105652_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-025-02332-8","article-title":"Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus, a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring","volume":"24","author":"Jiao","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105652_bib20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3349\/ymj.2023.0096","article-title":"Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy","volume":"64","author":"Jung","year":"2023","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.critrevonc.2026.105652_bib21","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1158\/1078-0432.CCR-18-1128","article-title":"Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma","volume":"24","author":"Kato","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105652_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251414103","article-title":"Prognostic value of ctDNA-derived maximum somatic allele frequency in patients with metastatic gastric cancer","volume":"18","author":"Kim","year":"2026","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib23","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/s41416-025-03113-2","article-title":"Oncogenic NFE2L2 mutations in plasma ctDNA and tumors are predictors and prognosticators of chemoradiation therapy in resectable esophageal squamous cell carcinoma","volume":"133","author":"Ko","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105652_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.109625","article-title":"Clinical value of preoperative circulating tumor DNA before surgery in patients with esophageal squamous cell carcinoma","volume":"51","author":"Kobayashi","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib25","article-title":"Circulating tumor DNA as a prognostic biomarker for recurrence in patients with locoregional esophagogastric cancers with a pathologic complete response","volume":"8","author":"Lander","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41467-020-14310-3","article-title":"White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer","volume":"11","author":"Leal","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105652_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.70017","article-title":"Exploring the clinical value of perioperative ctDNA-based detection of molecular residual disease in patients with esophageal squamous cell carcinoma","volume":"16","author":"Li","year":"2025","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105652_bib28","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s44321-024-00115-0","article-title":"Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction","volume":"16","author":"Li","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105652_bib29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejso.2012.01.008","article-title":"MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma","volume":"38","author":"Ling","year":"2012","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib30","article-title":"A clinical prognostic model for patients with esophageal squamous cell carcinoma based on circulating tumor DNA mutation features","volume":"12","author":"Liu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib31","article-title":"Circulating tumor DNA analysis for prediction of prognosis and molecular insights in patients with resectable gastric cancer, results from a prospective study","volume":"6","author":"Liu","year":"2025","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.critrevonc.2026.105652_bib32","article-title":"ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma","volume":"6","author":"Liu","year":"2025","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105652_bib33","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer, ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib34","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","article-title":"Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma","volume":"25","author":"Maron","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105652_bib35","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-22-3769","article-title":"Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer","volume":"29","author":"Maron","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105652_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70242","article-title":"Circulating tumor DNA informs clinical practice in patients with recurrent\/metastatic gastroesophageal cancers","volume":"132","author":"Mehta","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105652_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/1354750X.2023.2201664","article-title":"Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer, a meta-analysis","volume":"28","author":"Min","year":"2023","journal-title":"Biomark."},{"key":"10.1016\/j.critrevonc.2026.105652_bib38","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1245\/s10434-023-13194-z","article-title":"Tumor burden monitoring with circulating tumor DNA during treatment in patients with esophageal squamous cell carcinoma","volume":"30","author":"Morimoto","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-024-03244-8","article-title":"Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors","volume":"31","author":"Nakamura","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105652_bib40","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer, ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib41","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2020.12.010","article-title":"Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling","volume":"32","author":"Ococks","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib42","first-page":"17","article-title":"Circulating Tumor DNA (ctDNA) in Gastroesophageal Adenocarcinoma (GEA), Evidence and Emerging Applications","author":"Sahwan","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105652_bib43","article-title":"Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma","volume":"8","author":"Shim","year":"2025","journal-title":"ESMO Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib44","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1136\/gutjnl-2020-322658","article-title":"EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers","volume":"70","author":"Smyth","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.critrevonc.2026.105652_bib45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/SLA.0000000000006699","article-title":"Circulating Tumor DNA assessment to predict risk of recurrence after surgery in patients with locally advanced esophageal squamous cell carcinoma, a prospective observational study","volume":"284","author":"Takei","year":"2025","journal-title":"Ann. Surg."},{"key":"10.1016\/j.critrevonc.2026.105652_bib46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s43856-025-00867-x","article-title":"Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma","volume":"5","author":"Tougeron","year":"2025","journal-title":"Commun. Med. (Lond. )"},{"key":"10.1016\/j.critrevonc.2026.105652_bib47","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s10120-022-01313-w","article-title":"Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer","volume":"25","author":"van Velzen","year":"2022","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2026.105652_bib48","article-title":"Circulating tumor DNA predicts prognosis at different time points in patients with esophageal cancer, a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1116","article-title":"Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma","volume":"12","author":"Wang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105652_bib50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ebiom.2019.04.003","article-title":"Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer","volume":"43","author":"Wang","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105652_bib51","first-page":"203","article-title":"Detection of circulating tumor cell DNA for monitoring advanced gastric cancer","volume":"13","author":"Wu","year":"2020","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib52","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1111\/1759-7714.14610","article-title":"Assessment of durable chemoimmunotherapy response via circulating tumor DNA in advanced esophageal squamous cell carcinoma","volume":"13","author":"Yang","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105652_bib53","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41419-020-2531-z","article-title":"Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105652_bib54","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231225038","article-title":"Analysis of circulating tumor DNA identifies distinct therapeutic response to intraperitoneal and intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis","volume":"16","author":"Yuan","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105652_bib55","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/cac2.12494","article-title":"Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer","volume":"43","author":"Yuan","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.critrevonc.2026.105652_bib56","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1038\/s41467-025-62056-7","article-title":"Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma, the PLAGAST prospective biomarker study","volume":"16","author":"Zaanan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105652_bib57","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1097\/JS9.0000000000001373","article-title":"Association between plasma circulating tumor DNA and the prognosis of esophageal cancer patients, a meta-analysis","volume":"110","author":"Zhang","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105652_bib58","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1186\/s12885-025-14790-w","article-title":"Novel surveillance protocol for gastric cancer based on CEA, a high-volume multi-center study","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105652_bib59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12885-024-11879-6","article-title":"An update of clinical value of circulating tumor DNA in esophageal cancer, a systematic review and meta-analysis","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105652_bib60","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s13258-023-01412-7","article-title":"Postoperative circulating tumor DNA detection and CBLB mutations are prognostic biomarkers for gastric cancer","volume":"45","author":"Zhou","year":"2023","journal-title":"Genes. Genom."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:30:52Z","timestamp":1792618252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":60,"alternative-id":["S1040842826005391"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105652","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of circulating tumor DNA in esophageal and gastric cancer by treatment stage: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105652"}}